newsfilter
← Latest News
GlobeNewswire·

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business